BDR Pharma’s Acquisition Expands Its Pharmaceutical Manufacturing Platform
BDR Pharma expands its pharmaceutical manufacturing footprint
BDR Pharmaceuticals International Pvt. Ltd. is acquiring a controlling stake in Acme Formulation Pvt. Ltd.’s oral solid formulations business and its subsidiaries from existing investors, including private equity firm PAG. The companies announced the transaction in a statement. A person familiar with the matter put the business’s expected valuation at about $250 million. O3 Capital served as BDR Pharma’s exclusive financial advisor.
The acquisition adds capabilities in thyroid products, female sex hormones, and general medicines. BDR says the assets complement its existing therapeutic areas, which include oncology, critical care, and women’s healthcare, and could support growth in international markets.
How the acquisition fits BDR Pharma’s strategy
BDR plans to expand its contract development and manufacturing organization (CDMO) platform with a specialized base in oral solid formulations. The company expects to combine those capabilities with its portfolio of Abbreviated New Drug Applications (ANDAs) and products for the U.S. market. It says the acquired infrastructure and available capacity may help it transition more of its own products into commercial manufacturing.
Potential strategic benefits
- Adds manufacturing capabilities in thyroid and women’s health products.
- Broadens BDR’s product offering and manufacturing footprint.
- Creates opportunities to support customers in the U.S. and other international markets.
BDR Pharma, founded in 2003, operates in complex generics, finished formulations, and active pharmaceutical ingredients. Chairman and managing director Dharmesh Shah said Acme would strengthen the company’s CDMO platform and add differentiated capabilities.
Acme’s Immacule business remains with PAG and its founder
Following the sale, PAG and Acme founder Viral Shah will retain full ownership of Immacule, an India-based contract manufacturing business focused on sterile products. PAG partner and co-head of private equity Nikhil Srivastava said the owners intend to focus on developing Immacule as a global sterile injectables platform.
Immacule has commissioned a facility with stated capacity exceeding 200 million units per year. Its dosage-form capabilities include liquid and lyophilized vials, pre-filled syringes, and cartridges. Its therapeutic areas include oncology, ophthalmology, and general injectable drugs.
What the deal means for injectable drug manufacturing
The transaction separates Acme’s oral solids business from its sterile manufacturing operations. BDR gains the oral formulations assets, while Immacule remains under its current owners. Shah said he would work with BDR on a smooth transition while focusing on Immacule’s growth. The companies’ statements outline strategic plans; they do not establish specific timelines for product transfers or market launches.
- BDR Pharma acquires control of Acme’s oral solid formulations business and subsidiaries.
- PAG and Viral Shah retain ownership of Immacule and its sterile manufacturing operations.
- The reported valuation is approximately $250 million, according to a person familiar with the matter.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.